Treatment-Resistant Depression: Some Introductory Tips
The Carlat Psychiatry Report, Volume 16, Number 6&7, July 2018
Chris Aiken, MD
Editor-in-chief of The Carlat Psychiatry Report
Practicing psychiatrist, Winston-Salem, NC.
Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Treatment-resistant depression (TRD) has a fairly low barrier of entry. Failure of 2 full antidepressant trials—lasting 6 weeks at a minimally effective dose—is enough to qualify. In this month’s issue of TCPR, we’ll highlight pharmacologic advances that are underutilized and debunk a few that are unlikely to be effective for TRD.